GlaxoSmithKline (GSK) and the Singapore Economic Development Board (EDB) have pledged S$50 million to research in environmental and sustainable manufacturing and healthcare policy, and today handed out around S$5 million funding for eight research projects.
The recipients of this first round of funding include the Institute of Chemical and Engineering Sciences (ICES), Nanyang Technological University (NTU) and the National University of Singapore (NUS), and will research chemical-, physical- and bio-transformations so as to optimise resource efficiency, as well as reduce manufacturing waste.
Of the S$50 million committed, S$33 million will go to funding research in developing local capabilities in sustainable manufacturing. This joint fund falls under GSK-Singapore 10-year Strategic Roadmap, which seeks to provide innovative solutions for challenges faced by the industry.
EDB Chairman Mr Leo Yip shared that this is an encouraging move forward.
“Singapore is proud to partner GSK to grow our capabilities and talent base in green and sustainable manufacturing. This partnership will help to establish a research talent base in Singapore capable of developing more sustainable manufacturing processes in the pharmaceuticals and fine chemicals sectors,” he said.
